Association between plasma somatic copy number variations and response to immunotherapy in patients with programmed death-ligand 1-negative non-small cell lung cancer

OBJECTIVE: To determine how patients with non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1)-negative and/or a low tumor mutation burden status benefit from immune checkpoint inhibitors (ICI). METHODS: We determined the plasma cell-free DNA profiles of 25 patients with PD-L1-n...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaochen, Wang, Yina, Xiang, Jingjing, Zhao, Pan, Xun, Yanping, Zhang, Shirong, Xu, Nong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Pre-Clinical Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047987/
https://www.ncbi.nlm.nih.gov/pubmed/35466753
http://dx.doi.org/10.1177/03000605221093222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047987/
https://www.ncbi.nlm.nih.gov/pubmed/35466753
http://dx.doi.org/10.1177/03000605221093222

Ejemplares similares